{"id":24003,"date":"2020-11-11T00:00:00","date_gmt":"2020-11-11T05:00:00","guid":{"rendered":"https:\/\/www.cancerresearch.org\/media-room\/2020\/pd-1-l1-combination-drug-trial-strategies-increase\/"},"modified":"2022-09-12T14:15:44","modified_gmt":"2022-09-12T18:15:44","slug":"pd-1-l1-combination-drug-trial-strategies-increase","status":"publish","type":"cri_news","link":"https:\/\/www.cancerresearch.org\/es\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase","title":{"rendered":"La combinaci\u00f3n de f\u00e1rmacos gana terreno en el desarrollo de la inmunooncolog\u00eda de los ensayos cl\u00ednicos con inhibidores de PD-1 y PD-L1, seg\u00fan un nuevo informe del Cancer Research Institute\ufffc"},"content":{"rendered":"\n

NUEVA YORK, 11 de noviembre de 2020 \u2014 El Cancer Research Institute (CRI), organizaci\u00f3n sin fines de lucro consagrada al descubrimiento y desarrollo de inmunoterapias eficaces para todos los tipos de c\u00e1ncer, anunci\u00f3 hoy la publicaci\u00f3n en la revista Nature Reviews Drug Discovery <\/em>de su \u00faltimo an\u00e1lisis sobre el panorama a nivel mundial del desarrollo de f\u00e1rmacos inhibidores de PD-1\/PD-L1 para el tratamiento del c\u00e1ncer. El informe, titulado \u00abCombinations take centre stage in PD1\/PDL1 inhibitor clinical trials\u00bb<\/a>   (Las combinaciones adquieren protagonismo en los ensayos cl\u00ednicos de inhibidores de PD1 y PDL1), analiza las principales tendencias en tratamientos cl\u00ednicos e inscripci\u00f3n de pacientes de ensayos con anticuerpos monoclonales dirigidos a PD-1\/PD-L1 (AcM). Estos tratamientos son ahora el tratamiento habitual para 17 tipos diferentes de c\u00e1ncer y dos indicaciones pantumorales. Este \u00faltimo an\u00e1lisis es la continuaci\u00f3n de los informes anteriores del CRI sobre este tema, publicados entre 2017 y 2019.<\/p>\n\n\n\n

\u00abDesde que llevamos a cabo nuestro primer estudio del escenario de los AcM PD-1 y PD-L1 en 2017, la cantidad de estudios cl\u00ednicos que incluyen este tipo de inmunoterapia aument\u00f3 significativamente, sobre todo los ensayos que combinan los anticuerpos que bloquean la PD-1 o PD-L1 con otras formas de tratamiento \u2014dijo Samik Upadhaya, Ph. D., analista investigador del Anna-Maria Kellen Clinical Accelerator del CRI y primer autor del informe\u2014. Este \u00faltimo an\u00e1lisis revela una tendencia claramente definida hacia las estrategias combinadas: se duplic\u00f3 el n\u00famero de estos ensayos en el \u00faltimo a\u00f1o y se cuadruplic\u00f3 desde nuestro primer an\u00e1lisis en 2017\u00bb.<\/p>\n\n\n\n

En el informe elaborado por el CRI en colaboraci\u00f3n con IQVIA, proveedor l\u00edder a nivel mundial de an\u00e1lisis avanzados, soluciones tecnol\u00f3gicas y servicios de investigaci\u00f3n cl\u00ednica para el sector de las ciencias biol\u00f3gicas, se analizan tambi\u00e9n otras tendencias en el desarrollo cl\u00ednico global de PD-1\/PD-L1, incluida la disminuci\u00f3n en la inscripci\u00f3n prevista de ensayos de monoterapia, as\u00ed como una reducci\u00f3n en el n\u00famero de nuevos ensayos que combinan anticuerpos monoclonales anti-PD-1\/ PD-L1 con anticuerpos monoclonales anti-CTLA-4. En cambio, el informe muestra un aumento de los ensayos combinados dirigidos a las v\u00edas PD-1\/PD-L1 y VEGF\/R (angiog\u00e9nesis), as\u00ed como de aquellos que incluyen nuevos agentes inmunooncol\u00f3gicos dise\u00f1ados para eludir otros mecanismos de resistencia y aumentar la eficacia general de estos tratamientos combinados.<\/p>\n\n\n\n

Por \u00faltimo, el informe tambi\u00e9n advierte una disminuci\u00f3n general en las tasas de inscripci\u00f3n de pacientes en el \u00faltimo a\u00f1o, con datos reales de ensayos en la mayor\u00eda de las regiones del mundo, a pesar del aumento significativo del n\u00famero de ensayos.<\/p>\n\n\n\n

\u00abLa reducci\u00f3n de las tasas de inscripci\u00f3n de pacientes a nivel mundial puede deberse al impacto de la pandemia de COVID-19 en la investigaci\u00f3n cl\u00ednica \u2014dijo Jay Campbell, director general del Clinical Accelerator del CRI, cuyo equipo public\u00f3 a principios de este a\u00f1o un an\u00e1lisis del impacto de la COVID-19 en el desarrollo oncol\u00f3gico mundial\u2014. Hasta tanto no se eval\u00fae el impacto general de la pandemia no se sabr\u00e1 si esta tendencia pueda continuar, y es algo que estamos monitoreando de cerca.\u00bb<\/p>\n\n\n\n

Para acceder a un panel interactivo del informe, visite el sitio web del CRI cancerresearch.org\/pd1l1-landscape<\/a>.<\/p>\n\n\n\n

Referencia:
Upadhaya S, Neftelinov ST, Hodge JP, Oliva C, Campbell JR, Yu JX. Las combinaciones adquieren protagonismo en los ensayos cl\u00ednicos de inhibidores de PD1\/PDL1. Nat. Rev. Drug Discov.<\/em> https:\/\/www.nature.com\/articles\/d41573-020-00204-y<\/a><\/p>\n\n\n\n\n\n

Acerca del Cancer Research Institute<\/strong>
El Cancer Research Institute (CRI), fundado en 1953, es la organizaci\u00f3n sin fines de lucro l\u00edder a nivel mundial, consagrada a salvar m\u00e1s vidas al promover el descubrimiento y desarrollo de inmunoterapias eficaces para tratar todos los tipos de c\u00e1ncer. Asesorado por un Consejo Asesor Cient\u00edfico de renombre mundial, que incluye a cuatro premios Nobel y 26 miembros de la Academia Nacional de Ciencias, el CRI ha invertido 445 millones de d\u00f3lares para apoyar la investigaci\u00f3n que realizan los inmun\u00f3logos e inmun\u00f3logos tumorales de los centros m\u00e9dicos y las universidades m\u00e1s destacados del mundo. Asimismo, el CRI ha contribuido a lograr muchos de los principales avances cient\u00edficos que demuestran el potencial de la inmunoterapia para cambiar la manera de tratar el c\u00e1ncer. Para obtener m\u00e1s informaci\u00f3n, visite el sitio cancerresearch.org<\/a>.<\/p>\n\n\n\n

Acerca del Anna-Maria Kellen Clinical Accelerator<\/strong>
El programa cl\u00ednico del CRI, el Anna-Maria Kellen Clinical Accelerator, es un modelo \u00fanico de colaboraci\u00f3n y sin fines de lucro entre la academia y la industria, que sirve como \u00abincubadora\u00bb de ensayos cl\u00ednicos multic\u00e9ntricos para lograr nuevas combinaciones de inmunoterapia prometedoras. El fondo de filantrop\u00eda del CRI financia los ensayos cl\u00ednicos de este programa, que promueve un entorno colaborativo que permite a los cient\u00edficos presentar ideas de investigaci\u00f3n ambiciosas y acelera los estudios que un grupo o una empresa no podr\u00eda hacer individualmente. Para obtener m\u00e1s informaci\u00f3n sobre el Anna-Maria Kellen Clinical Accelerator, visite el sitio cancerresearch.org\/clinical-accelerator<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report from Cancer Research Institute reveals.<\/p>\n","protected":false},"featured_media":16389,"template":"","tags":[393,401,426],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-24003","cri_news","type-cri_news","status-publish","has-post-thumbnail","hentry","tag-checkpoint-inhibitors-es","tag-clinical-accelerator-es","tag-io-landscape-es"],"acf":[],"yoast_head":"\nCombination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline<\/title>\n<meta name=\"description\" content=\"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Combination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline\" \/>\n<meta property=\"og:description\" content=\"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-12T18:15:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Combination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline\" \/>\n<meta name=\"twitter:description\" content=\"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials.\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase\",\"url\":\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase\",\"name\":\"Combination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg\",\"datePublished\":\"2020-11-11T05:00:00+00:00\",\"dateModified\":\"2022-09-12T18:15:44+00:00\",\"description\":\"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg\",\"width\":700,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Media Room Article\",\"item\":\"https:\/\/www.cancerresearch.org\/media-room\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"La combinaci\u00f3n de f\u00e1rmacos gana terreno en el desarrollo de la inmunooncolog\u00eda de los ensayos cl\u00ednicos con inhibidores de PD-1 y PD-L1, seg\u00fan un nuevo informe del Cancer Research Institute\ufffc\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Combination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline","description":"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase","og_locale":"es_ES","og_type":"article","og_title":"Combination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline","og_description":"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials.","og_url":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase","og_site_name":"Cancer Research Institute","article_modified_time":"2022-09-12T18:15:44+00:00","og_image":[{"width":700,"height":500,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_title":"Combination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline","twitter_description":"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials.","twitter_misc":{"Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase","url":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase","name":"Combination Drug Strategies Gain Ground in PD-1\/PD-L1 Pipeline","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg","datePublished":"2020-11-11T05:00:00+00:00","dateModified":"2022-09-12T18:15:44+00:00","description":"New report from Cancer Research Institute reveals combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/71183132-f150-4bff-b28a-53b53c85d0b5.jpg","width":700,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/media-room\/pd-1-l1-combination-drug-trial-strategies-increase#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Media Room Article","item":"https:\/\/www.cancerresearch.org\/media-room"},{"@type":"ListItem","position":3,"name":"La combinaci\u00f3n de f\u00e1rmacos gana terreno en el desarrollo de la inmunooncolog\u00eda de los ensayos cl\u00ednicos con inhibidores de PD-1 y PD-L1, seg\u00fan un nuevo informe del Cancer Research Institute\ufffc"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news\/24003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/16389"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=24003"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tags?post=24003"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=24003"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=24003"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=24003"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=24003"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=24003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}